Stay updated with breaking news from Drug Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants Nirsevimab would be the first immunization specifically designed to protect all... | June 8, 2023
FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants Nirsevimab would be the first immunization specifically designed to protect
FinancialContent fully hosted finance channel
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab's consistent and high efficacy against infant hospitalizations
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy against infant hospitalizations due to RSVData presented at ESPID add to the body of evidence demonstrating nirsevi...